Trials / Completed
CompletedNCT07368855
GLP-1 Medicines and Mental Health Changes
Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- University of California, San Diego · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality. Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.
Detailed description
In a sample of veterans with obesity and established metabolic disease receiving supervised GLP-1 treatment for weight loss, we observed a consistent pattern of improved psychiatric health, eating disorder behaviors, and health-related quality of life. In addition to observing statistically significant changes across all the latter dimensions using validated psychometric measures, effect size magnitudes were also large enough to suggest potentially clinically meaningful improvements. Importantly, we observed robust evidence of decreases in depressive symptoms - averaging 30% declines in symptom severity - with no signs of increased suicidal ideation symptoms in the sample. The smaller size of this sample necessarily warrants additional research to validate these findings across the broader veteran population and among non-veteran samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLP-1 | Wegovy or Zepbound |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2026-01-27
- Last updated
- 2026-01-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07368855. Inclusion in this directory is not an endorsement.